This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Richard E. Ostlund, Jr, MD; Myrlene A. Staten, MD; Wendy M. Kohrt, PhD; Kathleen A. Obert, RD; William H. Daughaday, MD
Washington University School of Medicine St Louis, Mo

JAMA. 1991;266(14):1937-1938.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Apolipoprotein B (apo B) is the principal protein component of the atherogenic lipoproteins low-density (LDL) and very-low-density (VLDL). The factors that regulate plasma apo B levels are of particular interest since in some data apo B is more closely related to coronary heart disease than LDL or VLDL cholesterol.¹ We wondered whether insulin-like growth factor I (IGF-I) might be such a factor since the infusion of recombinant IGF-I recently was reported to lower plasma cholesterol levels.^2-4 Indeed, previous work had shown that IGF-I deficiency states were accompanied by hypercholesterolemia.^5-7 Our hypothesis was that apo B—containing lipoproteins were inversely related to circulating IGF-I in normal subjects.

Insulin-like growth factor I,⁸ insulin-like growth factor II (IGF-II),⁹ and apo B¹⁰ were measured in serum frozen at —70° obtained from 148 well-characterized, healthy men and women between the ages of 60 and 70 years for . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?